NEKTAR THERAPEUTICS (NKTR): Nasdaq/NYSE listing notice — Nektar receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule

NEKTAR THERAPEUTICS

Notice dated May 26, 2023; stock closed below $1.00 for 30 consecutive business days.
Company has until November 22, 2023 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant, may qualify for second 180-day period by transferring to Nasdaq Capital Market.
Company intends to monitor bid price and evaluate options including possible reverse stock split.
No immediate impact on listing; delisting possible if compliance not achieved.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

NEKTAR THERAPEUTICS received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

May 26, 2023, Nektar Therapeutics (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Global Select Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”) because the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Com

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-045748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.